Therapeutic plasma exchange in a critically ill Covid-19 patient.
Aged
Albumins
C-Reactive Protein
/ analysis
COVID-19
/ complications
Combined Modality Therapy
Critical Illness
/ therapy
Cytokine Release Syndrome
/ blood
Fibrinogen
/ analysis
Humans
Interleukin-6
/ blood
Male
Oxygen
/ blood
Oxygen Inhalation Therapy
Plasma Exchange
Pneumonia, Ventilator-Associated
/ etiology
Respiration, Artificial
/ adverse effects
Respiratory Distress Syndrome
/ blood
SARS-CoV-2
Salvage Therapy
Solutions
SARS-CoV-2
critically ill Covid-19
cytokine release syndrome
cytokine storm
plasma exchange
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
23
06
2020
revised:
29
07
2020
accepted:
30
07
2020
pubmed:
3
9
2020
medline:
27
2
2021
entrez:
3
9
2020
Statut:
ppublish
Résumé
Here we describe the effect of therapeutic plasma exchange with 5% albumin as sole replacement solution for the management of Covid-19. A 74-year-old man was admitted for severe Covid-19 acute respiratory distress syndrome. Based on the growing body of evidence that cytokine release syndrome, and especially interleukin-6, plays a key role in critically ill Covid-19 patients, we decided to implement therapeutic plasma exchange as a rescue therapy. The patient's clinical status rapidly improved, and biological records showed convincing results of decrease in interleukin-6 and inflammatory parameters under treatment. This case presents a proof-of-concept for the use of therapeutic plasma exchange with 5% albumin as sole replacement solution in a critically ill Covid-19 patient with cytokine release syndrome. This could constitute a major benefit in terms of security compared to long-lasting immunosuppressive monoclonal antibodies, or to therapeutic plasma exchange with plasma as replacement fluid. Hence, we think that a further evaluation of risk-benefit balance of this therapy in severe cases of Covid-19 should rapidly be undertaken.
Substances chimiques
Albumins
0
IL6 protein, human
0
Interleukin-6
0
Solutions
0
Fibrinogen
9001-32-5
C-Reactive Protein
9007-41-4
Oxygen
S88TT14065
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-182Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Wang C, Fei D, Li X, Zhao M, Yu K. IL-6 may be a good biomarker for earlier detection of COVID-19 progression. Intensive Care Med. 2020;46:1-2. https://doi.org/10.1007/s00134-020-06065-8.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033-1034.
Colafrancesco S, Scrivo R, Barbati C, Conti F, Priori R. Targeting the immune system for pulmonary inflammation and cardiovascular complications in COVID-19 patients. Front Immunol. 2020;11:1439.
Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care. 2020;24(1):128 s13054-020-2836-4.
Knaup H, Stahl K, Schmidt BMW, et al. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care. 2018;22(1):285.
Rimmer E, Houston BL, Kumar A, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis. Crit Care. 2014;18(6):699.
Reeves JH. A review of plasma exchange in sepsis. Blood Purif. 2002;20:282-288.
Zhang L, Zhai H, Ma S, Chen J, Gao Y. Efficacy of therapeutic plasma exchange in severe COVID-19 patients. Br J Haematol. 2020;190:e181-e232. https://doi.org/10.1111/bjh.16890.
Shi H, Zhou C, He P, et al. Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection. Int J Antimicrob Agents. 2020;56:105974.
Ma J, Xia P, Zhou Y, et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin Immunol. 2020;214:108408.
Reverberi R, Reverberi L. Removal kinetics of therapeutic apheresis. Blood Transfus. 2007;5(3):164-174.
Brown BL, McCullough J. Treatment for emerging viruses: convalescent plasma and COVID-19. Transfus Apher Sci. 2020;59(3):102790.